Recall Ledger

Theophylline Extended-Release Tablets recall (Brandywine Pharmaceuticals, LLC)

DrugClass IIOngoing

Summary: Brandywine Pharmaceuticals, LLC is recalling Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.. Reason: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory.

What is being recalled

Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-501-10.

Why

CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory

How serious is it

Class II is the middle level: using or being exposed to this product may cause temporary or medically reversible health problems, and the chance of serious harm is remote.

Where it was sold

Nationwide within U.S

How to tell if yours is affected

Lot: 405620, Expiry: 03/31/2028.

What to do

Check the product name, lot number and expiration date on your package against the codes above. If they match, do not stop taking a prescription medicine without talking to your doctor or pharmacist first; ask them about a replacement. Return or dispose of the product as your pharmacy advises.

Recall facts

Recall numberD-0111-2027
CategoryDrug
AgencyU.S. Food and Drug Administration (FDA)
SeverityClass II
StatusOngoing
Recall startedOctober 6, 2026
ReportedNovember 4, 2026
CompanyBrandywine Pharmaceuticals, LLC
Company locationWest Chester, PA, United States
Initiated byVoluntary: Firm initiated
Quantity1,332 100-count bottles

More recalls from Brandywine Pharmaceuticals, LLC · all drug recalls · recalls from October 2026

Official FDA record